BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang TY, Wang RF, Bu ZY, Targher G, Byrne CD, Sun DQ, Zheng MH. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol 2022. [PMID: 35013596 DOI: 10.1038/s41581-021-00519-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Pan XY, Liu WY, Zhu PW, Li G, Tang LJ, Gao F, Huang OY, Yuan HY, Targher G, Byrne CD, Wang XD, Zheng MH. Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male. Hepatol Int 2022. [PMID: 35829867 DOI: 10.1007/s12072-022-10384-x] [Reference Citation Analysis]
2 Calder PC. Early biochemical observations point to nutritional strategies to manage non-alcoholic fatty liver disease. Clin Sci (Lond) 2022;136:1019-23. [PMID: 35775425 DOI: 10.1042/CS20220380] [Reference Citation Analysis]
3 Tao X, Chen L, Zhao Y, Liu Y, Shi R, Jiang B, Mi Y, Xu L. A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease. Front Med 2022;9:862879. [DOI: 10.3389/fmed.2022.862879] [Reference Citation Analysis]
4 Samimi S, Rajabzadeh S, Rabizadeh S, Nakhjavani M, Nakhaei P, Avanaki FA, Esteghamati A. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes. Eur J Med Res 2022;27:112. [PMID: 35818084 DOI: 10.1186/s40001-022-00731-x] [Reference Citation Analysis]
5 Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-peralta F. Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. JCM 2022;11:968. [DOI: 10.3390/jcm11040968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Mantovani A, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A. MAFLD and CKD: An Updated Narrative Review. IJMS 2022;23:7007. [DOI: 10.3390/ijms23137007] [Reference Citation Analysis]
7 Calder PC. Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2022;25:248-55. [PMID: 35762160 DOI: 10.1097/MCO.0000000000000845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Skopelja-Gardner S, An J, Elkon KB. Role of the cGAS-STING pathway in systemic and organ-specific diseases. Nat Rev Nephrol 2022. [PMID: 35732833 DOI: 10.1038/s41581-022-00589-6] [Reference Citation Analysis]
9 Zhang H, Zheng KI, Zhu PW, Chen SD, Li G, Ma HL, Tang LJ, Huang OY, Byrne CD, Targher G, Wang XD, Zheng MH. Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched case-control study. Eur J Gastroenterol Hepatol 2022. [PMID: 35694803 DOI: 10.1097/MEG.0000000000002392] [Reference Citation Analysis]
10 Zhang XL, Wang TY, Targher G, Byrne CD, Zheng MH. Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. Diabetes Metab J 2022;46:391-401. [PMID: 35656562 DOI: 10.4093/dmj.2022.0048] [Reference Citation Analysis]